"Core Binding Factors" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
Heterodimeric transcription factors containing a DNA-binding alpha subunits, (CORE BINDING FACTOR ALPHA SUBUNITS), along with a non-DNA-binding beta subunits, CORE BINDING FACTOR BETA SUBUNIT. Core Binding Factor regulates GENETIC TRANSCRIPTION of a variety of GENES involved primarily in CELL DIFFERENTIATION and CELL CYCLE progression.
| Descriptor ID |
D050660
|
| MeSH Number(s) |
D12.776.930.155
|
| Concept/Terms |
Core Binding Factors- Core Binding Factors
- Binding Factors, Core
- Factors, Core Binding
- PEBP2 Transcription Factor
- Transcription Factor, PEBP2
- Polyomavirus Enhancer Binding Protein 2
- Core-Binding Factor
- Core Binding Factor
|
Below are MeSH descriptors whose meaning is more general than "Core Binding Factors".
Below are MeSH descriptors whose meaning is more specific than "Core Binding Factors".
This graph shows the total number of publications written about "Core Binding Factors" by people in this website by year, and whether "Core Binding Factors" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 2018 | 1 | 0 | 1 |
| 2022 | 0 | 1 | 1 |
To return to the timeline,
click here.
Below are the most recent publications written about "Core Binding Factors" by people in Profiles.
-
KIT-mutated pediatric core-binding factor systemic mastocytosis-acute myeloid leukemia treated with avapritinib and decitabine. Pediatr Blood Cancer. 2024 Apr; 71(4):e30898.
-
Common kinase mutations do not impact optimal molecular responses in core binding factor acute myeloid leukemia treated with fludarabine, cytarabine, and G-CSF based regimens. Am J Hematol. 2023 03; 98(3):E53-E56.
-
Retrospective comparison of survival and responses to Fludarabine, Cytarabine, GCSF (FLAG) in combination with gemtuzumab ozogamicin (GO) or Idarubicin (IDA) in patients with newly diagnosed core binding factor (CBF) acute myelogenous leukemia: MD Anderson experience in 174 patients. Am J Hematol. 2022 11; 97(11):1427-1434.
-
Activity of decitabine as maintenance therapy in core binding factor acute myeloid leukemia. Am J Hematol. 2022 05; 97(5):574-582.
-
Core binding factor acute myelogenous leukemia-2021 treatment algorithm. Blood Cancer J. 2021 06 16; 11(6):114.
-
Secondary cytogenetic abnormalities in core-binding factor AML harboring inv(16) vs t(8;21). Blood Adv. 2021 05 25; 5(10):2481-2489.
-
Acute myeloid leukemia: Treatment and research outlook for 2021 and the MD Anderson approach. Cancer. 2021 04 15; 127(8):1186-1207.
-
Clinical Outcomes of Patients With Chronic Myeloid Leukemia With Concurrent Core Binding Factor Rearrangement and Philadelphia Chromosome. Clin Lymphoma Myeloma Leuk. 2021 05; 21(5):338-344.
-
Evolving strategies for the management of core-binding factor acute myeloid leukemia. Clin Adv Hematol Oncol. 2020 Nov; 18(11):691-694.
-
Comparison of therapy-related and de novo core binding factor acute myeloid leukemia: A bone marrow pathology group study. Am J Hematol. 2020 07; 95(7):799-808.